Twist Bioscience to acquire Abveris for $190M

By The Science Advisory Board staff writers

November 23, 2021 -- Twist Bioscience has entered into an agreement to purchase Abveris, a private in vivo antibody discovery firm, for $190 million.

Abveris offers antibody discovery services using its DiversimAb collection of hyperimmune mouse models, which can be used to develop biologics, according to Twist.

Twist launches new biotech firm
Twist Bioscience has launched a new biotechnology firm, Revelar Biotherapeutics, to develop and market an antibody discovered by Twist that neutralizes...
Twist launches exome panel for genomics research
Twist Bioscience has launched Exome 2.0, an exome panel for genomics research.
Twist Bioscience, Broad Institute partner
Twist Bioscience and the Broad Institute have created a custom next-generation sequencing target enrichment exome panel to be used to research cancer...
Abveris expands antibody discovery offerings with second Beacon system
Abveris has starting using a second Berkeley Lights Beacon optofluidic system to enable expansion of its antibody discovery offerings.
Abveris, Saccharo partner on antibody discovery
Abveris has entered into an antibody discovery partnership with Saccharo for the discovery of monoclonal antibodies to advance Saccharo's immuno-oncology...
Abveris, Immunitas partner on mAbs discovery
Abveris and Immunitas Therapeutics are partnering on the discovery of monoclonal antibodies (mAbs) to expand Immunitas' therapeutic pipeline.

Copyright © 2021

Cell Bio 2021
December 11-15
San Diego, California United States
Antibody Engineering and Therapeutics
December 13-17
San Diego, California United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter